Rossari Biotech’s Net Profit in June Quarter Down by 3.7%

Mumbai, July 21, 2025 – Rossari Biotech Limited (NSE: ROSSARI, BSE: 543213), a specialty chemicals manufacturer, reported its financial results for the quarter ended June 30, 2025. Its net profit in June quarter came down by 3.7%.

Consolidated Q1FY26 Financial Highlights (YoY)

Particulars	Q1FY26	Q1FY25	YoY Change
Revenue from Operations	₹543.7 Cr	₹489.7 Cr	▲ 11%
EBITDA	₹67.9 Cr	₹64.9 Cr	▲ 4.6%
EBITDA Margin	12.5%	13.3%	▼ 80 bps
PAT	₹33.6 Cr	₹34.9 Cr	▼ 3.7%
EPS (Diluted)*	₹6.1	₹6.3	▼

Standalone Q1FY26 Financial Highlights (YoY)

Particulars	Q1FY26	Q1FY25	YoY Change
Revenue from Operations	₹365.8 Cr	₹300.7 Cr	▲ 21.6%
EBITDA	₹43.9 Cr	₹39.8 Cr	▲ 10.3%
EBITDA Margin	12.0%	13.2%	▼ 120 bps
PAT	₹26.2 Cr	₹24.3 Cr	▲ 7.8%
EPS (Diluted)*	₹4.7	₹4.4	▲

*EPS not annualised

Segment Performance & Business Drivers

The Home, Personal Care and Performance Chemicals (HPPC) and Animal Health & Nutrition (AHN) segments were the key growth drivers in Q1FY26. The HPPC division saw a robust 16% YoY growth. This is majorly supported by deeper market penetration in agrochemicals, personal care, and institutional businesses. AHN recorded a 12% YoY rise. This rise reflects stable demand in animal nutrition.

However, the export business witnessed sequential softness though it remained ahead on a YoY basis.

Management Commentary

In a joint statement, Mr. Edward Menezes, Executive Chairman, and Mr. Sunil Chari, Managing Director, stated:

“We delivered a steady performance in Q1 FY26, with topline growth driven by strong momentum in our HPPC and AHN segments. Despite a challenging environment, our core businesses remained resilient… Our continued efficiency initiatives and focused efforts on optimising the product mix will drive growth in the coming quarters.”

They further emphasized strategic investments in capacity expansions aimed at catering to high-growth sectors such as personal care, oil & gas, pharma, and agrochemicals.

Strategic Outlook & Capacity Expansion

• Ongoing capacity expansion projects are progressing in a phased manner.
• Commissioning is expected over the next few quarters.
• Full-scale benefit from these expansions is projected to start from FY27, enhancing manufacturing agility and supply chain responsiveness.

Rossari Biotech Stock Performance

Rossari Biotech shares have declined 4.18% to ₹712.25 as of 9:54 AM IST on July 21, 2025. Rossari Biotech shares have declined 13% over the last year, down 12% year-to-date, and increased 6.33% in the previous month.

Rossari Biotech Ltd opened trading at ₹735.00 on the day, which also marked its intraday high. However, the stock touched a low of ₹697.35 during the session. The stock has seen a 52-week high of ₹972.70 and a 52-week low of ₹569.00, indicating a fairly broad trading range over the past year.

About Rossari Biotech

Rossari Biotech Limited is a BSE and NSE-listed specialty chemicals company based in Mumbai. It operates manufacturing facilities at Silvassa and Dahej and provides tailor-made solutions across HPPC, Textile Specialty Chemicals, and Animal Health & Nutrition segments. With a robust R&D backbone and pan-India distribution, Rossari caters to diverse applications in FMCG, industrial cleaning, textiles, personal care, and pet care industries.

REF: https://nsearchives.nseindia.com/corporate/ROSSARI_20072025154435_20250720_Intimation_of_Press_Release_Q1_FY26.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations